missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human KIN (aa 173-245) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (82%), Rat (82%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-65220 (PA5-65220. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Kin is a nuclear protein that forms intranuclear foci during proliferation and is redistributed in the nucleoplasm during the cell cycle. Short-wave ultraviolet light provokes the relocalization of the protein, suggesting its participation in the cellular response to DNA damage. Originally selected based on protein-binding with RecA antibodies, the mouse protein presents a limited similarity with a functional domain of the bacterial RecA protein, a characteristic shared by the human ortholog.
Specifications
Specifications
| Accession Number | O60870 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 22944 |
| Name | Human KIN (aa 173-245) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | antigenic determinant of rec-A protein; antigenic determinant of rec-A protein homolog; binding to curved DNA; Btcd; DNA/RNA-binding protein KIN17; HsKin17 protein; KIN; KIN, antigenic determinant of recA protein; KIN, antigenic determinant of recA protein homolog; KIN17; Kin17 DNA and RNA binding protein; Rts2 |
| Common Name | KIN |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction